We perform and develop all the required product-specific release and stability assays for your viral vaccine.
Development of virus manufacturing processes strongly depends on the availability of accurate and reproducible product characterization assays and release assays. Release tests for viral products typically include tests to measure quantity, potency, genetic stability, identity, residuals (e.g. host cell DNA, host cell protein and benzonase), and safety.
To determine which parameters are important to monitor during process development and which are important for release, the product needs to be characterized. Most of the techniques and assays that are used for product characterization are performed in-house. Some of these assays are developed to support process development, using representative material, and then validated for release of the final production. Our expert analytical staff covers all aspects from design to implementation and from development to validation of the assays according to ICH guidelines. Some compendial and most biosafety assays are outsourced to our qualified partners. For outsourcing, we can provide support across all areas, including selection of partners, quotation, temperature-controlled shipments, review and reporting in certificates of analysis.
Proper control must be established over the materials used when manufacturing viral vaccines. The use of animal-derived components is avoided as much as possible, and when unavoidable, must have traceability and testing in place to mitigate any risk of introduction and transfer of extraneous agents in the process. Extensive testing- by PCR for in vitro and in vivo adventitious agents- to confirm the absence of adventitious viruses in master cell banks (MCB) and master virus seeds (MVS) is performed according to ICH Q5A and ICH Q5D guidelines.
Another important parameter in monitoring virus production is the genetic stability. Here, the virus is propagated for a number of passages until or beyond the envisioned stage of commercial manufacturing (vaccines for human use-general considerations; http://www.usp.org/). Analysis of the genetic content is needed to assure that the strain is not altered during propagation. Extended propagation of the starting material provides the sensitivity required to detect any recombinants or mutants that have gained a growth advantage over the target strain. PCR detection combined with sequence analysis provides sufficient specificity and sensitivity to detect any variants in the transgene region that might arise. Next generation sequencing technologies can be employed to characterize virus variants that may be present at low frequencies in vaccine preparations or virus seeds.
We have ample experience in developing and qualifying assays, including (q)PCR, cell-based assays (FFA, PFA and TCID50), HPLC, SDS-PAGE, western blot, and ELISA. As such, we deploy a full range of assays required to successfully monitor the development and release of viral vaccines.